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Extracts and compounds of natural products have potential as alternatives to current Western medicines. However,
these products may not be patentable under the statutory requirements because of their naturally-occurring nature.
This article analyzes the current patenting practices for natural products in the United States, particularly in light of
the recent Supreme Court ruling in Myriad, and suggests an advantageous strategy for patenting these products.
Briefly, isolated natural products per se are not patentable in the United States. Therefore, patenting focus should
be placed on the modification, formulation, manufacture, and application of natural products. A detailed description
of each invention is highly recommended for stronger support and broader coverage of the claims.Background
Some natural products have gained popularity in pharma-
ceutical and healthcare industries for their therapeutic po-
tential. Numerous extracts and compounds isolated from
natural products are included in drugs and healthcare sup-
plements. For instance, a supplement of red clover isofla-
vones and a tablet of soy isoflavones were used to reduce
hot flushes in women [1,2], and extracts of valerian, hops,
and passion flower were blended into a sleep aid tablet to
improve sleep [3].
Patents offer exclusive rights to protect innovations and
achievements, and can attract investment to sustain and
strengthen further research. Chinese medicine research and
development substantially relies on preparing extracts and
compounds from natural materials, screening for bioactive
compounds effective for particular conditions or diseases,
and formulating these products into drugs and supple-
ments. Patent protection for these extracts and compounds
is desired. The patenting policy on natural products was re-
cently revisited in the United States in light of the recent
Supreme Court ruling in Myriad, which held that an iso-
lated DNA molecule from the human breast cancer-
susceptibility gene BRCA was patent-ineligible [4].
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article, unless otherwise stated.of Myriad, and provides suggestions and advice toward a
more advantageous strategy for patenting these products.
Are natural products patentable?
An invention must be new and useful to be patentable
in the United States [5]. Notably, laws of nature, natural
phenomena, and abstract ideas are excluded from
patent-eligible protection [6], because these naturally-
occurring matters are discovered rather than invented.
Natural products would not be awarded a patent merely
for their discovery. Patent eligibility is essentially differ-
ent from patentability. Patent eligibility means that the
invention is an item that can seek a protection under
patent law. In contrast, an invention becomes patent-
able when it meets the necessary requirements, such as
novelty, inventiveness, and industrial applicability, and a
patent can eventually be granted as well. Hence, a non-
natural compound is patent-eligible, but becomes un-
patentable if it is known.
The patent eligibility of natural products isolated or
purified from natural materials is less affirmatively defined.
The US patent law protects new, useful, and non-obvious
chemical compounds and compositions [7], encompassing
isolated and purified products from natural materials. It
has been intensively discussed in the Courts whether a
product isolated from natural materials is patent-eligible
or represents another kind of substance that should be
exempted from the “product of nature” doctrine. However,
the Courts adopt inconstant grounds and standards for
determining the patent eligibility of isolated naturaltral Ltd. This is an Open Access article distributed under the terms of the
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an isolated natural product needs to be from its natural
counterpart to be sufficient for exemption [8].
The Courts acknowledged that “even if [products] were
merely an extracted product without change, there is no
rule that such products are not patentable” [9]. However,
an isolated product would not be patentable for its im-
proved purity, unless it results in “properties and charac-
teristics which were different in kind from those of the
known product rather than in degree” [10]. A recrystal-
lized aspirin and a purified form of adrenalin were deemed
patentable because the purer forms were therapeutically
different from the natural forms [9,11]. In another case,
vitamin B12 purified from the fermentation of fungi was
considered to be of great therapeutic and commercial
worth [12]. Similarly in Chakrabarty, the Courts held that
a genetically engineered bacterium capable of breaking
down crude oil was patentable because the bacterium had
“markedly different characteristics from any found in na-
ture” [13]. In the above cases, the Courts took the view
that the isolation or purification had transformed the nat-
ural product to another “kind” of substance that was func-
tionally different from the natural product.
On the contrary, purified tungsten from tungsten ore
and a naturally-occurring bacterial strain were held to
be unpatentable because the Courts recognized that
the commercial usefulness of the purified tungsten and
bacteria could be attributed to their intrinsic proper-
ties [14,15]. In these cases, the patentees had simply
discovered “the natural qualities of the pure tungsten”
[14] and did not create “a state of inhibition or of non-
inhibition in the bacteria” [15]. The Courts adopted an
opposite view that a functional difference was insuffi-
cient for transforming a natural product to another
“kind” of substance.
An isolated product must be significantly distinct from
the natural form in a certain way to be patentable, regard-
less of the inconsistent rulings in the above cases. How-
ever, in the absence of robust standards for determining
whether a difference is “in kind” or “in degree”, or whether
it is a “marked difference”, the patentability of isolated nat-
ural products and the enforceability of patents for these
products remain ambiguous.
Recently, the “product of nature” doctrine was revis-
ited in Myriad, which invalidated a patent on an isolated
DNA molecule from the human cancer-susceptibility
gene BRCA [4]. The Supreme Court affirmed that an
isolated DNA molecule with an identical sequence to a
natural gene is a naturally-occurring product and not
patentable. On the other hand, a complementary DNA
(cDNA) of BRCA that had an intron removed was pa-
tentable because it is not naturally-occurring. However,
a short strand of cDNA that is indistinguishable from
natural DNA may not be patentable.In Myriad, the Supreme Court recognized that the pa-
tentee had isolated a DNA molecule from the human gen-
ome by severing the chemical bonds between nucleotides.
Although the isolated DNA molecule is not naturally-
occurring in any human body, the Supreme Court dis-
agreed that the isolation constituted an act of invention
and stated that the isolated DNA had no “markedly differ-
ent characteristics from any found in nature” [4]. The
Supreme Court also declined to agree that the severing
had created a non-naturally-occurring molecule because
the claims were not expressed in terms of the chemical
composition of the DNA but primarily concerned the gen-
etic information in the nucleotide sequence, which was
not created by the patentee.
In view of Chakrabarty [13], Myriad [4], and Mayo [16]
(in which the Courts invalidated diagnostic claims that
merely recited natural principles), the US patent office
(USPTO) revisited the patenting policy and issued a com-
prehensive examination guideline for natural matters on 4
March 2014 [17]. The guideline provides a list of factors
weighting for and against the patent eligibility of claims re-
citing or involving laws of nature/natural principles, nat-
ural phenomena, and natural products [17].
Under this guideline, the patent eligibility of a claim is
principally determined by considering whether the claim
recites something that is “significantly” or “markedly” differ-
ent from what exists, provided that not all differences rise
to the level of “marked differences” and that “a marked dif-
ference must be a significant difference, i.e., more than an
incidental or trivial difference” [17].
A functional difference, such as a new utility, is not a
mandatory weighting factor. Words such as “isolated”, “re-
combinant”, and “synthetic” add no weight to the patent
eligibility. However, a structural difference is a primary, but
not sole, criterion for patent eligibility. As seen in Myriad
[4], the structural difference of an isolated gene from the
chromosomal counterpart is not regarded as a “marked”
difference and is therefore patent-ineligible (page 5, line 11
of [17]). In contrast, the guideline determines that a syn-
thetic derivative of natural amazonic acid, 5-methyl amazo-
nic acid, has a “marked” structural difference from the
natural acid and is therefore patent-eligible (page 8, line 10
of [17]). Accordingly, a structural difference appears to be
important, but not necessarily sufficient, for patent eligibil-
ity. When a structural difference is absent or insignificant, a
functional difference may also be considered. A structural
difference is deemed sufficient for patent eligibility, whereas
a functional difference may or may not be considered in
chemical products. In the absence of a structural difference,
a natural product must exhibit new functions or character-
istics that rise to the level of “marked” differences to be
patent-eligible. Accordingly, amazonic acid purified from
the leaves of the Amazonian cherry tree is not significantly
different from the naturally-occurring amazonic acid, and
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contrary, a synthetic derivative of amazonic acid, 5-methyl
amazonic acid, is patent-eligible because it is structurally
different from the natural acid. Similarly, a product ob-
tained from a particular manufacturing process in a “prod-
uct-by-process” claim cannot survive if it has no structural
or “marked” difference from the natural form [17].
The same standard applies to the composition of multiple
natural products, that is, the composition remains a prod-
uct of nature if the combined products show no marked
difference from the natural products. However, manufac-
tures or compositions of natural products may be patent-
eligible if they include additional element(s) that would
make the products “something significantly different than
the natural products by themselves” [17].
A method of using natural products should involve a
practical, specific, and significant application of the natural
products such that the claimed method would not fore-
close others from using the same natural product in other
ways [17]. That is, the method should not merely recite:
(i) a general instruction to apply or use the natural prod-
ucts; (ii) well-understood, purely conventional, or routine
steps in the relevant field; or (iii) steps that need to be
used by anyone who applies or uses the natural products.
For instance, a method for treating a disease using a nat-
ural product should include additional step(s), such as a
regimen and dosage for administration of the natural
product used in the treatment, to limit the scope of the
claim. Accordingly, a method for treating colon cancer by
administering amazonic acid to a patient may not survive
as a significant application, whereas a method for treating
colon cancer by administering amazonic acid to a patient
for 10–20 days at a daily dose of 0.76–1.25 teaspoons
would satisfy the requirements [17].
Table 1 summarizes the patent eligibility of different types
of natural products and related methods under the new
examination policy of the USPTO. Under this policy, extracts
and isolated products from natural materials are likely to be
unpatentable. A formulation of combined extracts and iso-
lated products may be patentable if the combination results
in “markedly different” properties of the combined products,
e.g., enhanced efficacy at a lower dosage. Conversely, manu-
facturing methods such as extraction of natural products and
preparation of drugs and supplements using natural products
are still patentable if they satisfy other statutory requirements
such as novelty and non-obviousness (inventiveness).
Accordingly, a proper patenting strategy should focus on
derivatives of natural products with enhanced properties,
optimized formulations and dosages of natural products,
new uses or applications of natural products, and advanced
methods for preparing natural products. Claims should be
drafted within a reasonable scope and be of sufficient sig-
nificance so that they do not appear to be a general applica-
tion of the natural products.“Product-by-process” claims
There are circumstances in which a product cannot be
“truly” defined by features such as composing ingredients,
physical properties, and chemical structure. “Product-by-
process” claims define how a product is made, e.g., “prod-
uct X obtained by process Y” or “a product produced by
steps a, b, and c”. Sometimes, a “product-by-process”
claim is more desirable than a true product claim to cover
all possible products produced by a specific manufacturing
process, as it may be difficult to identify all possible em-
bodiments and combinations of the products. Most juris-
dictions only accept “product-by-process” claims when
there are no other possible means and only the manufac-
turing process can define the products. In the United
States, “product-by-process” claims are allowed if the
products could not otherwise be adequately defined [18].
In the United States, the patentability of “product-by-
process” claims is determined solely on the basis of the
product itself, regardless of the manufacturing process.
Therefore, a product identical to, or similar to, a known
product is not patentable even if it is manufactured by a
new or different method [19]. The manufacturing process
is taken into account only when the structure of the prod-
uct is “implied by the process steps” or the “process steps
would be expected to impart distinctive structural charac-
teristics to the final product” [20]. If the product claimed
is found to be identical or similar to any known products,
the applicants would bear the burden of proof on novelty
and non-obviousness of the claimed product to demon-
strate that the claimed product is distinguishable from the
known products [21].
A product isolated or synthesized by a particular process
would not be patentable if the patentee cannot prove that
the obtained product is non-naturally-occurring and mark-
edly different from the natural products [17]. Paradoxically,
the obtained product would be adequately defined if such
proof was available, and therefore not permitted to be de-
fined in a “product-by-process” claim.
Enforcement of “product-by-process” claims can be dif-
ficult because explicit characteristics of the product are
lacking. Notably, a “product-by-process” claim does not
necessarily cover all of the equivalent products that are
made by other methods, especially if the manufacturing
process involves special steps that make the product dis-
tinguishable from the known products.
When it comes to infringement, both the product and
the manufacturing process of “product-by-process” claims
are considered. “Product-by-process” claims only cover
products that are produced by the process recited in the
claim [22], and therefore an accused product made by a dif-
ferent process does not infringe a “product-by-process”
claim [23].
Accordingly, “product-by-process” claims may confer a
limited scope of protection and risk invalidation if the
Table 1 Summary of the patent eligibility of different types of natural products and related methods under the new









No No No Paclitaxel (taxol). /
Isolated or purified
extracts/chemicals
No No No Paclitaxel purified from Pacific yew tree. Page 7, Example
B of [17]
No Yes Maybe In the absence of a structural difference, the isolated
product needs to be combined with something
else that leads to a “marked” difference.
Compositions of
natural products
No No No Composition of paclitaxel and hydrogel as
a sustained-release and site-specific formulation.
Page 10–11,
Example D of [17]
No Yes Maybe Maybe patentable if the combination attains
“marked difference” in properties
of the natural products.
e.g. A sustained-release and site-specific
formulation of paclitaxel and hydrogel at 1:1
ratio with synergistically enhanced efficacy.




Yes No Yes Non-naturally-occurring derivative of paclitaxel. Page 8, Example
B of [17]
Compound obtained by a
manufacturing process
No No No Paclitaxel purified from Pacific yew tree





No Yes/No Yes Method of extracting paclitaxel





No N/A Maybe Patentable if the use is practical and significant. Page 8–9,
Example B of [17]
e.g. Treating ovarian cancer by administering
175 mg/m2 of paclitaxel intravenously
over 3 hours every 3 weeks to a patient.
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of the product is possible. Researchers are highly ad-
vised to include all features and available information
that may be useful, even inadequately, to characterize
the products in the application, as well as draft claims
based on the information. It is also desirable to draft
two sets of claims separately directed toward the
manufacturing process (process claim) and the product
(“product-by-process” claim) for a broader scope of
protection.
Sufficient disclosures
We usually draft claims reciting a general formula to
include a class of molecules sharing common struc-
tures or features. A person skilled in the art could de-
duce various embodiments of the invention. For
example, a person skilled in the art would envision that
CH4, C3H8, C100H202, and the like can fall within a
claim reciting the general formula (CnH2n+2). However,
contradictory to the common understanding, a claim
reciting a general formula is not patentable if only a
few species of the general formula have been disclosedin the application, and thereby only confers protection
on species that have been explicitly described in the
application [24]. The US patent law requires an inven-
tion to be sufficiently described in an application such
that one skilled in the art would recognize the inven-
tions. That is, if only CH4 and C3H8 have been identi-
fied in the application, claims directed toward the
general formula (CnH2n+2) are likely required to be lim-
ited to CH4 and C3H8.
A more detailed description would allow one to en-
compass more embodiments of an invention, and hence
achieve a broader scope of protection. It is highly rec-
ommended to explore all potential substitutions and
modifications of the invention within a reasonable
scope, and to disclose as many of these variations as
possible in the application. Claims should be drafted to
include all enabling and foreseeable embodiments of the
invention for subsequent research development and
marketing interests of the researchers. Detailed descrip-
tions should not be limited to products, but can also be
applied to other technical features such as temperature,
pH, and reagents used in the experiments.
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In view of the new examination policy, a patenting strategy
should focus on modifications, optimized formulations,
manufacturing methods, and specific applications of the
natural products. Disclosure of detailed information related
to the natural products in the application to comply with
the written descriptions and enablement requirements is
highly recommended. Identification and characterization of
individual embodiments and/or combinations thereof for
the invention are necessary for broader coverage of claims.
Frequent reviews and revisits of the developments in
patenting policy and their patenting strategy will help in-
ventors to better protect their inventions.
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